This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
How Much Upside is Left in Brainsway Ltd. Sponsored ADR (BWAY)? Wall Street Analysts Think 50.27%
by Zacks Equity Research
The consensus price target hints at a 50.3% upside potential for Brainsway Ltd. Sponsored ADR (BWAY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Best Momentum Stocks to Buy for November 22nd
by Zacks Equity Research
BWAY, RIGL and BROS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 22, 2023.
New Strong Buy Stocks for November 22nd
by Zacks Equity Research
RIGL, BWAY, AVDX, IMGN and EAT have been added to the Zacks Rank #1 (Strong Buy) List on November 22, 2023.
Is AC Immune (ACIU) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how AC Immune (ACIU) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year.
Has AVROBIO (AVRO) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how AVROBIO, Inc. (AVRO) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Brainsway (BWAY) This Year?
by Zacks Equity Research
Here is how Brainsway Ltd. Sponsored ADR (BWAY) and Align Technology (ALGN) have performed compared to their sector so far this year.
BrainsWay (BWAY) Expands Foothold in Taiwan With Deep TMS
by Zacks Equity Research
The collaboration between BrainsWay (BWAY) and Unison Healthcare Group signifies a coordinated effort to enhance access and awareness of Deep TMS in Taiwan.
Is Align Technology (ALGN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Align Technology (ALGN) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year.
Brainsway Ltd. Sponsored ADR (BWAY) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
by Zacks Equity Research
Brainsway Ltd. Sponsored ADR (BWAY) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
New Strong Sell Stocks for February 7th
by Zacks Equity Research
AMD, BWAY and DCOM have been added to the Zacks Rank #5 (Strong Sell) List on February 7, 2023.
New Strong Sell Stocks for February 1st
by Zacks Equity Research
BWAY, CMAX and EQBK have been added to the Zacks Rank #5 (Strong Sell) List on February 1, 2023.
New Strong Sell Stocks for January 30th
by Zacks Equity Research
BFC, CMAX and BWAY have been added to the Zacks Rank #5 (Strong Sell) List on January 30, 2023.
New Strong Sell Stocks for January 26th
by Zacks Equity Research
BWAY, INDB and CNX have been added to the Zacks Rank #5 (Strong Sell) List on January 26, 2023.
New Strong Sell Stocks for January 24th
by Zacks Equity Research
ABM, BWAY and DXPE have been added to the Zacks Rank #5 (Strong Sell) List on January 24, 2023.
New Strong Sell Stocks for January 19th
by Zacks Equity Research
ABM, BWAY and DXPE have been added to the Zacks Rank #5 (Strong Sell) List on January 19, 2022.
New Strong Sell Stocks for January 10th
by Zacks Equity Research
BWAY, BWAY and AXL have been added to the Zacks Rank #5 (Strong Sell) List on January 10, 2023.
Henry Schein (HSIC) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Henry Schein's (HSIC) Q2 performance will likely reflect continued strength in its dental and medical businesses.
IDEXX (IDXX) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
IDEXX's (IDXX) Q2 performance will likely benefit from strong sales from the CAG Diagnostics and Water businesses.
Brainsway Ltd. Sponsored ADR (BWAY) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
Brainsway Ltd. Sponsored ADR (BWAY) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Edwards Lifesciences (EW) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Edwards Lifesciences' (EW) Q2 performance will likely reflect the continued adoption of the RESILIA tissue valves and enhanced sales of the HemoSphere platform.
Exact Sciences (EXAS) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Exact Sciences' (EXAS) Q2 performance will likely reflect the benefit from continued adoption of the Oncotype DX breast test and robust Cologuard screening revenues.
Charles River (CRL) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
The broad-based demand and meaningful price increases in the RMS business, particularly in North America and China, are expected to have contributed to Charles River's (CRL) Q2 top line.
STERIS (STE) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
STERIS' (STE) Key Surgical and Cantel Medical businesses make significant contributions to consumable revenues within the Healthcare arm in Q1.
Bio-Rad (BIO) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Bio-Rad's (BIO) Clinical Diagnostics segment is expected to report growth in Q2, driven by its focus on laboratory workflow productivity, quality control, and new opportunities in molecular diagnostics.
Zimmer Biomet (ZBH) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Zimmer Biomet's (ZBH) S.E.T. arm is expected to deliver strong results on the back of the company's focus on sports and extremities, especially upper extremities, trauma and CMFT.